These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 28192597)

  • 21. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
    Apolo AB; Nadal R; Tomita Y; Davarpanah NN; Cordes LM; Steinberg SM; Cao L; Parnes HL; Costello R; Merino MJ; Folio LR; Lindenberg L; Raffeld M; Lin J; Lee MJ; Lee S; Alarcon SV; Yuno A; Dawson NA; Allette K; Roy A; De Silva D; Lee MM; Sissung TM; Figg WD; Agarwal PK; Wright JJ; Ning YM; Gulley JL; Dahut WL; Bottaro DP; Trepel JB
    Lancet Oncol; 2020 Aug; 21(8):1099-1109. PubMed ID: 32645282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
    Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
    Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
    Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
    Schöffski P; Gordon M; Smith DC; Kurzrock R; Daud A; Vogelzang NJ; Lee Y; Scheffold C; Shapiro GI
    Eur J Cancer; 2017 Nov; 86():296-304. PubMed ID: 29059635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.
    Peng H; Zhang Q; Li J; Zhang N; Hua Y; Xu L; Deng Y; Lai J; Peng Z; Peng B; Chen M; Peng S; Kuang M
    Oncotarget; 2016 Mar; 7(13):17220-9. PubMed ID: 26967384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.
    O'Sullivan Coyne G; Kummar S; Hu J; Ganjoo K; Chow WA; Do KT; Zlott J; Bruns A; Rubinstein L; Foster JC; Juwara L; Meehan R; Piekarz R; Streicher H; Sharon E; Takebe N; Voth AR; Bottaro D; Costello R; Wright JJ; Doroshow JH; Chen AP
    Clin Cancer Res; 2022 Jan; 28(2):279-288. PubMed ID: 34716194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
    Powles T; Choueiri TK; Motzer RJ; Jonasch E; Pal S; Tannir NM; Signoretti S; Kaldate R; Scheffold C; Wang E; Aftab DT; Escudier B; George DJ
    BMC Cancer; 2021 Aug; 21(1):904. PubMed ID: 34364385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
    Drilon A; Rekhtman N; Arcila M; Wang L; Ni A; Albano M; Van Voorthuysen M; Somwar R; Smith RS; Montecalvo J; Plodkowski A; Ginsberg MS; Riely GJ; Rudin CM; Ladanyi M; Kris MG
    Lancet Oncol; 2016 Dec; 17(12):1653-1660. PubMed ID: 27825636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
    Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
    PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
    Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.
    Cabanillas ME; Brose MS; Holland J; Ferguson KC; Sherman SI
    Thyroid; 2014 Oct; 24(10):1508-14. PubMed ID: 25102375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
    Luo X; Jia W; Huang Z; Li X; Xing B; Jiang X; Li J; Si A; Yang T; Gao C; Lau WY; Shen F
    Oncotarget; 2017 Mar; 8(10):17246-17257. PubMed ID: 27783997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cabozantinib in progressive medullary thyroid cancer.
    Elisei R; Schlumberger MJ; Müller SP; Schöffski P; Brose MS; Shah MH; Licitra L; Jarzab B; Medvedev V; Kreissl MC; Niederle B; Cohen EE; Wirth LJ; Ali H; Hessel C; Yaron Y; Ball D; Nelkin B; Sherman SI
    J Clin Oncol; 2013 Oct; 31(29):3639-46. PubMed ID: 24002501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.
    Corn PG; Zhang M; Nogueras-Gonzalez GM; Xiao L; Zurita AJ; Subudhi SK; Tu SM; Aparicio AM; Coarfa C; Rajapakshe K; Huang S; Navone NM; Lin SH; Wang G; Ramachandran S; Titus MA; Panaretakis T; Gallick GE; Efstathiou E; Troncoso P; Logothetis C
    Clin Cancer Res; 2020 Mar; 26(5):990-999. PubMed ID: 31941830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
    Leibowitz-Amit R; Pintilie M; Khoja L; Azad AA; Berger R; Laird AD; Aftab DT; Chi KN; Joshua AM
    J Transl Med; 2016 Jan; 14():12. PubMed ID: 26762579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
    Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
    J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
    Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
    Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
    Qun W; Tao Y
    Hepatogastroenterology; 2010; 57(99-100):426-9. PubMed ID: 20698202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.